Exclusivity Fee. Commencing with the first anniversary of the Effective Date, and continuing with each successive anniversary until the initiation of the first Phase III Clinical Trial for the Product, Intrexon shall pay to Halozyme the non-refundable and non-creditable exclusivity fee of one million dollars ($1,000,000).
Appears in 2 contracts
Sources: Collaboration and License Agreement (Intrexon Corp), Collaboration and License Agreement (Intrexon Corp)
Exclusivity Fee. Commencing with the first anniversary of the Effective Date, and continuing with each successive anniversary until the initiation of the first Phase III Clinical Trial for the Product, Intrexon shall pay to Halozyme the non-refundable and non-creditable exclusivity fee of one million [*****] dollars ($1,000,000[*****]).
Appears in 1 contract
Sources: Collaboration and License Agreement (Intrexon Corp)